Interim Report January - June 2009 Tripep AB (publ)

Interim Report January - June 2009 Tripep AB (publ)

 Research and development costs amounted to SEK 3.1 (11.8) m
 The loss after tax was SEK -6.4 (-18.1) m
 Earnings per share were SEK -0.28 (-1.92)
 Net sales SEK 0.4 (-) m
 All patients in the ChronVac-C® study have now received all vaccinations. A
total of 12 patients has now been treated with ChronVac-C® and no severe adverse
events have been recorded. Virological and immunological analyses are ongoing
and results are scheduled to be made public during the 4th quarter of 2009
 Data from the ChronVac-C® study was presented as oral presentations at the
annual meeting of the European Association for the Study of the Liver in
Copenhagen, Denmark, April 23rd, and at the annual meeting of the American
Society for Gene Therapy in San Diego May 28th
 The multi-center study on ChronSeal® is ongoing in Sweden and Norway. An
interim analysis of the treatment effect will be performed no later than October
31st and published shortly thereafter

Events after the end of the reporting period
 The company has carried out two private placements after the end of the
reporting period raising SEK 6 m through the placements
 Tripep has out licensed the RAS® technology to Opsonic Therapeutics 



For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.